UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
January 3, 2005
SUPERGEN, INC.
(Exact name of registrant as specified in its charter)
Delaware | | 0-27628 | | 91-1841574 |
(State or other jurisdiction of
incorporation) | | (Commission File Number) | | (IRS Employer
Identification No.) |
4140 Dublin Blvd., Suite 200
Dublin, CA 94568
(Address of principal executive offices, including zip code)
(925) 560-0100
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On January 3, 2005, SuperGen, Inc. (“SuperGen”) and MGI PHARMA, Inc. (“MGI”) announced that the New Drug Application seeking approval of Dacogen™ (decitabine) for injection has been accepted for filing by the U.S. Food and Drug Administration. Dacogen is an investigational anti-cancer therapeutic for the treatment of patients with myelodysplastic syndromes. MGI has exclusive worldwide rights to the development, manufacture, commercialization and distribution of Dacogen.
On January 3, 2005, SuperGen and MGI issued a press release announcing this event, a copy of which is filed as an exhibit to this report and is incorporated in this report by reference.
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits
Exhibit No. | | Description |
| | |
99.1 | | Press release dated January 3, 2005. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | SUPERGEN, INC. |
| | |
| By: | /s/ MICHAEL MOLKENTIN |
| | Michael Molkentin |
| | Chief Financial Officer |
Date: January 4, 2005
3
EXHIBIT INDEX
Exhibit
No. | | Description |
| | |
99.1 | | Press release dated January 3, 2005. |
4
